Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Gemtuzumab Ozogamicin in AML and High-Risk MDS
NCT00882102Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2009
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, gemtuzumab ozogamicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2009; status: completed.
02
Drugs
decitabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00882102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882102.